Core Viewpoint - A class action lawsuit has been filed against WPP PLC, alleging that the company misled investors about its business prospects and financial performance during the specified period [1][2]. Allegations - The complaint claims that WPP's management created a false impression of having reliable information regarding projected revenue and growth, while downplaying risks associated with seasonality and macroeconomic factors [2]. - It is alleged that WPP's optimistic reports on client acquisition and retention were misleading, as the company's media division was losing market share and was not effectively competitive [2]. Performance Update - On July 9, 2025, WPP issued a trading update indicating a deterioration in performance as the second quarter progressed, attributing this to macroeconomic uncertainties affecting client spending and weaker new business than expected [3]. - Following this announcement, WPP's stock price fell from $35.82 per share on July 8, 2025, to $29.34 per share on July 9, 2025, marking a decline of approximately 18.1% [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against WPP PLC, with options to serve as lead plaintiff or remain an absent class member [4]. - The representation in the class action is on a contingency fee basis, meaning shareholders incur no fees or expenses [5].

Core Viewpoint - A class action lawsuit has been filed against Cepton, Inc. alleging that the company misled investors regarding its acquisition by Koito Manufacturing Co., Ltd. [1][2] Group 1: Allegations - The lawsuit claims that Cepton did not disclose a credible third-party bid that valued the company at more than double the acquisition price offered by Koito, which was $3.17 per share [3] - It is alleged that Cepton's Board of Directors failed to adequately explore the third-party offer and did not disclose its terms when recommending the Koito acquisition to shareholders [3] - As a result of these actions, shareholders were deprived of the opportunity to make an informed decision regarding the acquisition [3] Group 2: Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers with the court by December 8, 2025 [4] - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4] Group 3: Firm Background - Robbins LLP is noted for its focus on shareholder rights litigation, helping shareholders recover losses and improve corporate governance since 2002 [5]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against The Trade Desk, Inc. due to a class action complaint alleging breaches of fiduciary duties by the company's board of directors during a specified class period [1][2]. Group 1: Class Action Details - The class action alleges that during the class period from May 9, 2024, to February 12, 2025, Trade Desk made materially false and misleading statements regarding its business operations and prospects [2]. - Specific allegations include significant execution challenges in rolling out the Kokai platform, which delayed its rollout and negatively impacted revenue growth [2]. Group 2: Next Steps for Investors - Long-term stockholders of Trade Desk are encouraged to contact Bragar Eagel & Squire for more information regarding their rights and potential claims related to the class action [3]. Group 3: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various complex litigations across state and federal courts [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Alto Neuroscience, Inc. (NYSE:ANRO) on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][6]. Company Overview - Alto Neuroscience, Inc. is facing scrutiny following a class action complaint filed on July 21, 2025, concerning the period from February 2, 2024, to October 22, 2024 [1]. - The complaint alleges that the Offering Documents related to Alto's IPO were negligently prepared and that the effectiveness of ALTO-100 in treating Major Depressive Disorder (MDD) was overstated [6]. Financial Impact - On October 22, 2024, Alto announced that ALTO-100 did not meet its primary endpoint in a Phase 2b trial for MDD, leading to a significant stock price drop of $10.17 per share, or 69.99%, closing at $4.36 per share on October 23, 2024 [6].

Core Viewpoint - A class action lawsuit has been filed against Fortinet, Inc. for allegedly misrepresenting the impact of unit upgrades of its FortiGate firewalls, leading to significant stock price decline when the truth was revealed [1][2][3]. Group 1: Allegations - The lawsuit claims that Fortinet failed to disclose the difficulty in predicting the total number of FortiGates requiring an upgrade [2]. - It is alleged that customers had excess firewall capacity from previous purchases, reducing the necessity for upgrades [2]. - The complaint states that the refresh of the firewalls had minimal business impact, as it represented only a small percentage of the company's business due to the age of the products [2]. Group 2: Stock Price Impact - Following the revelation of these allegations, Fortinet's stock price dropped over 22%, from $96.58 per share on August 6, 2025, to $75.30 per share on August 7, 2025 [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action against Fortinet and can contact Robbins LLP if they wish to serve as lead plaintiff [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4]. Group 4: Firm Background - Robbins LLP is recognized for its leadership in shareholder rights litigation, focusing on helping shareholders recover losses and improve corporate governance since 2002 [5].

Core Viewpoint - A class action lawsuit has been filed against Quanex Building Products Corporation for failing to disclose significant operational issues related to its Tyman acquisition, which led to a substantial decline in stock price when the information was revealed [2][3]. Group 1: Allegations and Issues - The lawsuit alleges that Quanex's maintenance procedures and policies at its Tyman Mexico facility were significantly underinvested, leading to degraded tooling and equipment conditions [2]. - It is claimed that these operational issues were previously identified by the company but not disclosed, resulting in misleading positive statements about its business and prospects [2]. Group 2: Stock Price Impact - Following the revelation of these issues, Quanex's stock price dropped by $2.73, or 13.1%, closing at $18.18 per share on September 5, 2025 [3]. - The stock continued to decline, falling an additional $1.98, or 10.9%, to close at $16.20 per share on September 8, 2025 [3]. Group 3: Class Action Participation - Shareholders may be eligible to participate in the class action, with a deadline to file as lead plaintiff by November 18, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

Core Viewpoint - A class action has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have resulted in financial losses for shareholders [2]. Group 1: Allegations and Legal Action - The class action is on behalf of individuals and entities that purchased Cytokinetics securities between December 27, 2023, and May 6, 2025 [1]. - The complaint alleges that Cytokinetics made materially false and misleading statements about the NDA submission and approval process for aficamten, specifically regarding the expected approval timeline from the U.S. Food and Drug Administration (FDA) [2]. - Defendants claimed that approval was expected in the second half of 2025, based on a PDUFA date of September 26, 2025, while failing to disclose risks related to the submission of a Risk Evaluation and Mitigation Strategy [2]. Group 2: Participation and Representation - Shareholders interested in serving as lead plaintiffs must submit their papers by November 17, 2025, to represent other class members in the litigation [3]. - Shareholders can choose not to participate in the case and still remain eligible for recovery as absent class members [3]. Group 3: Company Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Strategy Incorporated (NASDAQ:MSTR) on behalf of long-term stockholders due to a class action complaint alleging breaches of fiduciary duties by the board of directors [1][2]. Group 1: Allegations and Claims - The class action complaint filed on May 16, 2025, covers a Class Period from April 30, 2024, to April 4, 2025, and alleges that the defendants made materially false and misleading statements regarding Strategy's business and operations [1][2]. - Specific allegations include overstating the anticipated profitability of the company's bitcoin-focused investment strategy and treasury operations, underestimating the risks associated with bitcoin's volatility, and failing to disclose the potential magnitude of losses on digital assets following the adoption of ASU 2023-08 [2]. Group 2: Next Steps for Investors - Long-term stockholders of Strategy who have information or questions regarding the claims are encouraged to contact Bragar Eagel & Squire, P.C. for further discussion [3].

Core Viewpoint - A class action lawsuit has been filed against Fly-E Group, Inc. for allegedly misleading investors about its revenue projections and sales performance during a specified period [1][2]. Company Overview - Fly-E Group, Inc. operates in the electric vehicle sector, specifically designing, installing, and selling smart electric motorcycles, electric bikes, electric scooters, and related accessories under the Fly E-Bike brand in the United States, Mexico, and Canada [1]. Allegations - The lawsuit claims that Fly-E Group misrepresented its revenue outlook and sales expectations, creating a false impression of reliable information regarding its financial performance [2]. - The complaint highlights that Fly-E's optimistic revenue goals did not align with actual demand for its electric vehicle products, and the company downplayed risks related to lithium batteries, supply chain issues, and regulatory challenges [2]. Financial Performance - On August 14, 2025, Fly-E reported a significant 32% decrease in net revenue compared to the same period in 2024, primarily attributed to a decline in total units sold due to consumer hesitance linked to lithium battery explosion incidents [3]. - Following the revenue announcement, Fly-E's stock price plummeted approximately 87%, from $7.76 per share to $1.00 per share within a single day [3]. Legal Proceedings - Shareholders are encouraged to participate in the class action lawsuit, with options to serve as lead plaintiff or remain as absent class members [4]. - Robbins LLP, the law firm handling the case, operates on a contingency fee basis, meaning shareholders incur no upfront costs [5].

Core Viewpoint - A class action lawsuit has been filed against Cytokinetics, Inc. for allegedly misleading investors regarding the New Drug Application (NDA) submission timeline for aficamten, which may have caused financial losses to shareholders [2]. Group 1: Allegations and Legal Proceedings - The lawsuit claims that Cytokinetics made materially false statements about the expected approval timeline for aficamten, indicating that approval from the U.S. FDA was anticipated in the second half of 2025, based on a PDUFA date of September 26, 2025 [2]. - The company allegedly failed to disclose significant risks related to its inability to submit a Risk Evaluation and Mitigation Strategy, which could delay the regulatory process [2]. - Shareholders experienced financial losses when the truth about the NDA submission was revealed [2]. Group 2: Participation and Representation - Shareholders may be eligible to participate in the class action and those wishing to serve as lead plaintiff must submit their papers by November 17, 2025 [3]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required to be eligible for recovery [3]. Group 3: Firm Background - Robbins LLP is a recognized leader in shareholder rights litigation, dedicated to helping shareholders recover losses and improve corporate governance since 2002 [4].